0.03
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ACRO Biomedical Co
From its filings with the US Securities and Exchange Commission
ACRO Biomedical Co is based in Fishers, Indiana and is incorporated in Nevada. Its shares trade on OTC under the ticker ACBM. The SEC classifies its business as amusement & recreation services. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $101,146. At that date it held total assets of $14,098 and shareholders' equity of −$386,964.
Since January 30, 2017, following a change of control, our business has been the development and marketing nutritional products that promote wellness and a healthy lifestyle. Our revenue to date has resulted from the purchase of products from three suppliers in the Republic of China (Taiwan), one of which accounted for all of our purchases in the year ended December 31, 2022. We have not generated any revenue in the second and third quarters of 2022 and subsequent to December 31, 2022 through the date of this annual report, and we did not purchase any inventory since the second quarter of 2022.
Substantially all of our sales to date have been sales of cordyceps related products. Cordyceps is a fungus that is used in traditional Chinese medicine. Cordyceps sinensis has been described as a medicine in old Chinese medical books and Tibetan medicine. It is a rare combination of a caterpillar and a fungus and found at altitudes above 4500m in Sikkim. We may also seek to market other products which we see as complimentary to our present products; however, we have not entered into negotiations with respect to the distribution of other products and we cannot assure you that we will be able to market any other products. In the quarter ended June 30, 2018, we sold metallothionein MT-3 elizer. We do consider metallothionein MT-as part of our business.
Quoted from its 10-K, filed 11 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 23 Jun 2016
- Employees
- 1
- Website
- acrobiomedicalco.com ↗
- Head office
- 12175 VISIONARY WAY, FISHERS, IN, 46038
- Incorporated in
- NV
- Classification
- Services-Amusement & Recreation Services
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Su Yu- TingChairman of the Board, Chief Executive Officer, since 2025
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ACRO Biomedical Co Ltd has several strengths that contribute to its success. Firstly, the company possesses a strong research and development team, enabling them to develop innovative medical products. This technical expertise gives them a competitive advantage in the market. Additionally, ACRO Biomedical has established strategic partnerships with key industry players, enhancing their distribution network and market reach. Moreover, the company has a solid reputation for delivering high-quality and reliable medical solutions, building trust among customers.
Weaknesses
- Despite their strengths, ACRO Biomedical also faces certain weaknesses. One of the main challenges is their limited brand recognition, particularly in international markets. This makes it difficult for the company to penetrate new markets effectively. Additionally, ACRO Biomedical may encounter difficulties in scaling up production due to resource constraints. Moreover, the company's current product portfolio may lack diversification, making them vulnerable to changes in market demand.
Opportunities
- ACRO Biomedical can leverage several opportunities to further grow its business. Firstly, there is a rising global demand for advanced medical products, driven by an aging population and increasing healthcare expenditure. This provides ACRO Biomedical with a vast market to expand into. Additionally, the company can explore emerging markets that have a growing need for medical solutions but are currently underserved. Moreover, technological advancements and evolving medical regulations present opportunities for ACRO Biomedical to develop and commercialize new products.
Threats
- ACRO Biomedical faces certain threats that could impact its performance. One crucial threat is intense competition from established medical device companies. These competitors may have greater financial resources, brand recognition, and distribution capabilities. Another significant threat is regulatory uncertainties and compliance issues in different regions. Non-compliance with regulations could lead to delays in product approvals and market entry. Furthermore, market dynamics and shifting customer preferences pose a threat to ACRO Biomedical's market share.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.